Dan Pollyea, MD, MS

Articles by Dan Pollyea, MD, MS

The AML Treatment Horizon

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

August 3rd 2023

Experts on acute myeloid leukemia offer closing thoughts and discuss emerging treatments in the field.

Determining Which Patients Will Benefit the Most From Menin Inhibitor Treatment

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

August 3rd 2023

The expert panel provide clinical insights on which patients with AML may benefit the most from treatment with menin inhibitors.

The Role of Menin Inhibitors in the AML Treatment Armamentarium

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

August 3rd 2023

The panel of experts share their thoughts on where menin inhibitors will offer the most benefit in the overall treatment regimen for patients with AML.

Menin Inhibitors in the Second-Line Treatment of AML

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 27th 2023

The expert panel discuss emerging data on menin inhibitors in the second-line treatment of AML, including an overview of the KOMET-001 trial evaluating ziftomenib.

Exploring Potential Combination Treatments for AML

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 27th 2023

Experts on acute myeloid leukemia share clinical insights on first-line combination therapies, including the potential role of menin inhibitors in this setting.

The Potential Role of Menin Inhibitors in the Front-Line Treatment of AML

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 20th 2023

The expert panel review recently reported data from clinical trials evaluating menin inhibitors, including ziftomenib and revumenib, in the treatment of relapsed AML and how these treatments may fit into first-line settings.

First-Line Treatment Options for AML With KMT2a Rearrangements

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 20th 2023

Daniel Pollyea, MD, MS, discusses first-line treatment options for patients with AML with KMT2a rearrangements.

First-Line Treatment Options for NPM1-mutant AML

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 13th 2023

Eunice S. Wang, MD, shares first-line treatment approaches for patients with NPM1-mutant AML, discussing current clinical data.

Treatment Options for a Young, Fit Patient Newly Diagnosed with AML

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 13th 2023

The panel discuss the need for personalized treatment approaches for young, fit patients with newly diagnosed acute myeloid leukemia, as well as when transplant should be considered.

Treating Newly Diagnosed Acute Myeloid Leukemia

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 6th 2023

Daniel Pollyea, MD, MS, discusses how he assesses patients with newly diagnosed acute myeloid leukemia for the best first-line therapy, including the role of intensive induction chemotherapy.

Barriers to Molecular Testing in AML

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

July 6th 2023

Eunice S. Wang, MD, offers an overview of common barriers to performing molecular testing in community practices, including uncertainty about which tests to perform and the wait times for results.

When to Perform Molecular Testing in Relapsed AML

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

June 22nd 2023

Harry P. Erba, MD, PhD, discusses the need to retest for mutations including IDH1, IDH2, FLT3, NPMI, and KMT2A rearrangement for patients with relapsed or refractory acute myeloid leukemia.

The Role of Molecular Testing in Diagnosing Acute Myeloid Leukemia

ByNaval Daver, MD,Harry P. Erba, MD, PhD,Dan Pollyea, MD, MS,Eunice S. Wang, MD

June 22nd 2023

A panel of clinical experts provide insights about the importance of molecular and cytogenetic testing in diagnosing acute myeloid leukemia and in determining the best treatment plan.

Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML

ByDan Pollyea, MD, MS

January 21st 2021

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML

ByDan Pollyea, MD, MS

January 14th 2021

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

Daniel A. Pollyea, MD, on the Impact of Venetoclax in IDH-Mutant AML

ByDan Pollyea, MD, MS

December 30th 2020

The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.